Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Alaska Permanent Fund Corp

Alaska Permanent Fund Corp lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 177,378 shares of the biopharmaceutical company’s stock after selling 25,031 shares during the period. Alaska Permanent Fund Corp’s holdings in Gilead Sciences were worth $14,369,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. OFI Invest Asset Management purchased a new position in Gilead Sciences in the third quarter worth approximately $26,000. Tompkins Financial Corp grew its position in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC purchased a new position in Gilead Sciences in the fourth quarter worth approximately $29,000. Rakuten Securities Inc. purchased a new position in Gilead Sciences in the fourth quarter worth approximately $33,000. Finally, Financial Connections Group Inc. purchased a new position in Gilead Sciences in the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD traded up $0.40 during trading on Thursday, reaching $67.48. The company’s stock had a trading volume of 597,665 shares, compared to its average volume of 7,229,048. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86. The company’s fifty day moving average price is $71.56 and its 200-day moving average price is $76.39. The company has a market capitalization of $84.02 billion, a price-to-earnings ratio of 14.98, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $1.67 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 5.24 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.56%. Gilead Sciences’s payout ratio is 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GILD shares. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Barclays lowered their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Oppenheimer restated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Finally, UBS Group lowered their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $84.57.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.